Drug Trial Radar · NCT07145151
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Jun 4, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose,6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.
Conditions
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
UBT251Drug
UBT251 administered subcutaneously (SC) once a week.
PlaceboDrug
Placebo,SC,once a week for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver HistologyTime frame: Baseline, Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua ChangGung Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.